Job Title: Associate Director, Health Economics & Outcomes Research

Department: Medical Affairs

Location: Princeton, NJ

About Summit:

Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational

bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.

Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:

• HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).

• HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

• HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.

Overview of Role:

Summit Therapeutics is seeking an Associate Director, Health Economics & Outcomes Research, to join our mission of developing Ivonescimab, a novel and unique immunotherapy with the potential to help patients suffering from life-threatening cancers.

The Associate Director of Health Economics and Outcomes Research (HEOR) will lead initiatives to generate and communicate evidence that enhances product value and informs access strategies. This position entails developing and executing comprehensive health economics, outcomes research, and real-world evidence (RWE) plans in alignment with medical affairs strategies, clinical development objectives, and commercial approaches to support product value propositions and optimize market access. The role is responsible for disseminating scientific evidence to inform providers, payers, population-based decision makers (PBDMs), and patients about the value proposition of ivonescimab.

The ideal candidate will thrive in a fast-paced environment and be adept at collaborating with internal cross-functional teams and external stakeholders.

Role and Responsibilities:

• Lead HEOR research activities including planning, budgeting, and on time execution
• Author and review protocols, analytic plans, reports and other study documents with independent, critical thinking to ensure quality and completeness of output
• Implement global and regional HEOR strategies and projects to inform, support, and strengthen market access
• Assist with value demonstration tactics for Health Technology Assessment (HTA) including the EU Join Clinical Assessment (JCA) and payer assessments
• Maintain awareness of the quickly evolving global HTA and reimbursement landscape
• Lead the development and implementation of robust RWE studies, economic models, clinical outcome assessments (COAs), patient preference studies, and other relevant research to meet value evidence needs
• Ensure evidence generation is conducted with a high level of scientific rigor and is in strategic alignment with cross-functional teams
• Oversee the development of high-quality publications, posters, and presentations to communicate HEOR findings effectively
• Collaborate with internal teams to package economic models and generated evidence into field materials that address payer and stakeholder priorities
• Develop and maintain strong alignment with the managed care liaison team to obtain insights from external stakeholders and adjust evidence generation plans accordingly
• All other duties as assigned

Experience, Education and Specialized Knowledge and Skills:

• Bachelor’s degree (Master’s, PharmD or PhD) in Health Economics, Epidemiology, Outcomes Research, Public Health or related field. Master’s preferred.
• 8+ years relevant experience in healthcare industry with direct experience in global value proposition development and interaction with payers, HTA bodies, relevant policymakers and strong patient-centered focus
• Previous experience in Oncology, preferably non-small cell lung cancer (NSCLC)
• Understanding of the US market access landscape; familiarity with global reimbursement processes a strong plus
• Hands on experience in health economics, health technology assessment (HTA) tools, methods and filing, SLRs, ITCs, statistical analyses, RWE generation and economic modelling
• Strong analytical capabilities and excellent communication skills
• Ability to work collaboratively across diverse teams and manage multiple stakeholders
• Ability to be proactive, enthusiastic and goal oriented
• Track record of peer-reviewed publications

The pay range for this role is $163,000-$191,500 annually. Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.

Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.